专利号:US-4704450-A 优先权日:1983-02-21 标 题 :Synthesis of hpGRF(Somatocrinin) in liquid phase and intermediate peptides 发明人:DIAZ JOSEPH; DEMARNE HENRI; RONCUCCI ROMEO; SCHMELCK PAUL-HENRY 权利人:SANOFI SA 摘要:The invention relates to synthesis of hpGRF (Somatocrinin) in liquid phase and to intermediate peptides, comprising: coupling, one after the other and in the order of the sequence of the GRF, the fragments in which: (a) the side acid functions of the aspartic and glutamic acids and the side amine function of the lysine are protected by protector groups stable in the conditions of deprotection of the group Boc, (b) the guanidine function of the arginine is protected by protonation, and (c) the N-terminal amino acid is protected on the amine by the Boc group; selectively eliminating the group Boc from the N-terminal amine of the peptide in phase of elongation by hydrolysis with trifluoroacetic acid, said coupling being effected in an aprotic polar solvent and eliminating, at the end of sequence, all the protector groups by hydrolysis with the aid of a 0.1 to 1M solution of methanesulfonic or trifluoromethanesulfonic acid in trifluoroacetic acid.
专利号:US-4581168-A 优先权日:1983-02-21 标题:Synthesis of hpGRF (Somatocrinin) in liquid phase and intermediate peptides 发明人:DIAZ JOSEPH; DEMARNE HENRI; RONCUCCI ROMEO; SCHMELCK PAUL-HENRY 权利人:SANOFI SA 摘要:The invention relates to synthesis of hpGRF (Somatocrinin) in liquid phase and to intermediate peptides, comprising:--coupling, one after the other and in the order of the sequence of the GRF, the fragments in which: (a) the side acid functions of the aspartic and glutamic acids and the side amine function of the lysine are protected by protector groups stable in the conditions of deprotection of the group Boc, (b) the guanidine function of the arginine is protected by protonation, and (c) the N-terminal amino acid is protected on the amine by the Boc group;--selectively eliminating the group Boc from the N-terminal amine of the peptide in phase of elongation by hydrolysis with trifluoroacetic acid, said coupling being effected in an aprotic polar solvent and--eliminating, at the end of sequence, all the protector groups by hydrolysis with the aid of a 0.1 to 1M solution of methanesulfonic or trifluoromethanesulfonic acid in trifluoroacetic acid.
专利号:US-4797469-A 优先权日:1984-07-10 标 题:Synthesis of hGRF (Somatocrinin) in liquid phase and intermediate peptides 发明人:DIAZ JOSEPH; DEMARNE HENRI; RONCUCCI ROMEO; SCHMELCK PAUL-HENRY 权利人:SANOFI SA 摘要:A process for the synthesis, in liquid phase and by fragments, of hGRF 1-44 and hGRF 1-40. This process consists in coupling, one after the other and in the order of the sequence of the GRF, (1) on the one hand, the following fragments: -H-Ala-Arg-Ala-Arg-Leu-NH2 called Fragment A hGRF (40-44) or - alaninamide (40) -H-Gln-Glu-Arg-Gly-OH called Fragment B'1 hGRF (36-39) -H-Glu-Ser-Asn-OH called Fragment B'2 hGRF (33-35) -H-Ser-Arg-Gln-Gln-Gly-OH called Fragment C hGRF (28-32) -H-Leu-Gln-Asp-Ile-Met-OH called Fragment D' hGRF (23-27) -H-Arg-Lys-Leu-OH called Fragment E'1 hGRF (20-22) - to obtain the peptide K1 [(hGRF (20-44)] on the corresponding peptide having the sequence (20-40) and (2) on the other hand, the following fragments: -H-Gln-Leu-Ser-Ala called Fragment F1 hGRF (16-19) -H-Tyr-Arg-Lys-Val-Leu-Gly OH called Fragment G1 hGRF (10-15) -H-Ile-Phe-Thr-Asn-Ser-OH called Fragment H1 hGRF (5-9) - to obtain the peptide J [hGRF (5-19)] and thereafter to couple together the peptides J and K1 in order to form the peptide having the sequence hGRF (5-44) or hGRF (5-40) and finally to couple the resulting peptide with the peptide H-Tyr-Ala-Asp-Ala-OH, called fragment I hGRF (1-4).
专利号:EP-0171315-B1 优先权日:1984-07-10 标题:Process for the synthesis of hgrf (somatocrinin) in the liquid phase, and intermediary peptides
专利号:CA-1267998-A 优先权日:1983-02-21 标题:Synthesis of hpgrf (somatocrinin) in liquid phase and intermediate peptides
专利号:EP-0122818-A1 优先权日:1983-02-21 标题:Liquid-phase synthesis of hpGRF (Somatocrinin) and intermediate peptides
参考标题:Synthesis Of The Octadecapeptide Corresponding To Positions 32 To 49 Of The Revised Amino Acid Sequence Of Thymopoietin Ii And Its Effect On Low E-Rosette Forming Cells Of An Aged Patient With Chronic Renal Failure. 作者:Takashi Abiko,Hiroshi Sekino 摘要:The Octadecapeptide, H-Arg-Lys-Asp-Val-Tyr-Val-Glu-Leu-Tyr-Leu-Gln-Ser-Leu-Thr-Ala-Leu-Lys-Arg-Oh, Corresponding To Positions 32 To 49 Of The Revised Amino Acid Sequence Of Bovine Thymopoietin Ii Was Synthesized By The Azide Condensation Of Three Fragments, (32-36), (37-41) And (42-49), Followed By Deprotection With Hydrogen Fluoride In The Presence Of Anisole-Thioanisole-O-Cresol. The In Vitro Addition Of The Synthetic Thymopoietin Ii (32-49) Significantly Restored The Low E-Rosette Forming Capacity Of Cells From An Aged Patient With Chronic Renal Failure To Normal Levels. The In Vitro Effect Of [gln38, Thr43, Val47]-Thymopoietin Ii (32-49) On The Low E-Rosette Forming Capacity Of Cells From The Aged Patient With Chronic Renal Failure Was Also Compared With That Of The Synthetic Thymopoietin Ii (32-49). The [gln38, Thr43, Val47]-Thymopoietin Ii (32-49) Was Approximately Equipotent With The Synthetic Thymopoietin Ii (32-49) At A Concentration Of 100 μg/ml.
合成参考文献
参考文献:10.1177/1087057116635503 摘要:Voter AF, Manthei KA, Keck JL. A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. J Biomol Screen. 2016 Jul;21(6):626–33.